Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 17/20 | 0.73 |
| ▸ | MMP1 | P03956 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP7 | P09237 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 2/20 | 0.54 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
| ▸ | MMP15 | P51511 | 2/20 | 0.54 |
| ▸ | MMP16 | P51512 | 2/20 | 0.54 |
| ▸ | MMP26 | Q9NRE1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862864 | 1.00 | GHSR (0.73) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3072393 | 1.00 | GHSR (0.73) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3080106 | 0.93 | GHSR (0.63) | GHSR | |
| SCHEMBL3075932 | 0.93 | GHSR (0.63) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3066630 | 0.92 | GHSR (0.62) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL14541631 | 0.92 | GHSR (0.62) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3074262 | 0.92 | GHSR (0.62) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3075509 | 0.92 | GHSR (0.62) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL14863165 | 0.91 | GHSR (0.73) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3067287 | 0.91 | GHSR (0.62) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | claimed |
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | GHSR 2277/4885MMP1 3015/4885MMP2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.